Pharmstandard posts FY 2008 Net Profit of 3.5 billion Roubles
Russian drugmaker, Pharmstandard, has posted a FY 2008 Net Profit of 3.5 billion Roubles under IFRS.
The bottom line was up 7% on the FY 2007 Net Profit with EBITDA rising 24% to 6.04 billion Roubles on Revenues of 14.47 billion Roubles, up 26%.
The company attributed the result to a promotional campaign on a range of products including anti viral drug Arbidol, and increase synergies stemming from the decision to transfer production of key drugs including Arbidol and Flukostat to Pharmstandard’s own production facilities.
You can share this story on social media: